Pemetrexed in Patients With Soft Tissue Sarcoma

Phase 2 Completed 54 enrolled University Hospital Tuebingen Arbeitsgemeinschaft fur Internistische Onkologie · collab German Sarcoma Group · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-based chemotherapy and to assess the toxicity profile

Timeline

Start: 2007-01
Primary completion: 2008-12
Completion: 2008-12

Publications

Hartmann JT, Bauer S, Egerer G, Horger MS, Kopp HG, Grunwald V, Mayer F. Pemetrexed in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005. Invest New Drugs. 2013 Feb;31(1):167-74. doi: 10.1007/s10637-012-9840-8. Epub 2012 Jul 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Pemetrexed in Patients With Soft Tissue Sarcoma

Summary

Timeline

Publications

Drugs

Indications